I think it would be premature to pass judgement on efficacy based on P2 trial, where efficacy measures are secondary end points. They also found useful biomarkers in the trial that may enable better patient selection for any future trials. Not an easy trial to undertake, but a lack of alternatives and the sound pre-clinical and safety data for 2256 may make another larger company want to take research further.
I think it would be premature to pass judgement on efficacy...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.03 |
Change
0.680(4.74%) |
Mkt cap ! $1.894B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.08 | $14.35 | $3.419M | 230.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18 | $15.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.04 | 169 | 3 |
View Market Depth
| Last trade - 13.12pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |